Showing results (261-270 of 285) with videos related to
Sort By:
Pageof 29
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.Hepatology (Baltimore, Md.)|December 3, 2003
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patientsEugene R Schiff, Ching-Lung Lai, Stefanos Hadziyannis, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 1, 2011
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian WorkshopGiampiero Carosi, Mario Rizzetto, Alfredo Alberti, et al.Hepatitis Monthly|November 2, 2016
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineSeyed Moayed Alavian, Behzad Hajarizadeh, Kamran Bagheri Lankarani, et al.Gut|August 22, 2014
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationLindsay Y King, Claudia Canasto-Chibuque, Kara B Johnson, et al.The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.JHEP Reports : Innovation in Hepatology|January 16, 2023
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practiceJeffrey V Lazarus, Laurent Castera, Henry E Mark, et al.Pageof 29